(Reuters) – The U.S. Food and Drug Administration on Monday asked Heron Therapeutics for additional data on its therapy to manage postoperative pain.
The company said the FDA did not identify any clinical safety or efficacy issues for the non-opioid painkiller, HTX-011.
(Reporting by Vishwadha Chander and Dania Nadeem in Bengaluru; Editing by Saumyadeb Chakrabarty)
